YCBD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2026Q1

4.70M

+3.2%

-0.160

-86.67%

5.29M

+3.49%

-0.050

-97.16%

Estimates Revision

The market is revising No Change the revenue expectations for cbdMD, Inc. (YCBD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 108.58%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+108.58%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.400

Low

2.00

Averages

2.00

High

2.00

Current: 1.400

Low

2.00

Averages

2.00

High

2.00

Maxim

Buy

downgrade

$3 -> $2

2025-08-20

Reason

Maxim

Price Target

$3 -> $2

2025-08-20

downgrade

Buy

Reason

Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.

Maxim

Buy

downgrade

$16 -> $3

2025-05-22

Reason

Maxim

Price Target

$16 -> $3

2025-05-22

downgrade

Buy

Reason

Valuation Metrics

The current forward P/E ratio for cbdMD Inc (YCBD.A) is -5.61, compared to its 5-year average forward P/E of -5.70. For a more detailed relative valuation and DCF analysis to assess cbdMD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.70

Current PE

-5.61

Overvalued PE

7.07

Undervalued PE

-18.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-54.21

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

127.27

Undervalued EV/EBITDA

-235.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.94

Current PS

0.54

Overvalued PS

2.13

Undervalued PS

-0.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

YCBD News & Events

Events Timeline

No data

News

4.5

12-12Benzinga

S&P 500 Declines 1%; Broadcom Reports Earnings Exceeding Expectations

4.5

12-12Benzinga

Dow Gains More Than 100 Points as Lululemon Reports Strong Q3 Earnings

7.0

12-08Newsfilter

cbdMD Regains NYSE Compliance, Removes Noncompliance Indicator

People Also Watch

Frequently Asked Questions

What is cbdMD Inc (YCBD) stock price today?

The current price of YCBD is 1.4 USD — it has increased 16.67 % in the last trading day.

What is cbdMD Inc (YCBD)'s business?

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

What is the price predicton of YCBD Stock?

What is cbdMD Inc (YCBD)'s revenue for the last quarter?

cbdMD Inc revenue for the last quarter amounts to 4.61M USD, decreased -10.96 % YoY.

What is cbdMD Inc (YCBD)'s earnings per share (EPS) for the last quarter?

cbdMD Inc. EPS for the last quarter amounts to -0.21 USD, decreased -82.50 % YoY.

What changes have occurred in the market's expectations for cbdMD Inc (YCBD)'s fundamentals?

How many employees does cbdMD Inc (YCBD). have?

cbdMD Inc (YCBD) has 42 emplpoyees as of December 15 2025.

What is cbdMD Inc (YCBD) market cap?

Today YCBD has the market capitalization of 10.70M USD.